Skip to main content
Equibles
TPST logo

TPST · Tempest Therapeutics, Inc. · Metrics

Track TPST — free

Use TPST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TPST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.81 +0.01 (+0.63%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 13, 2026
Market Cap
$12.28M
Shares
14.81M
Volume · Oct 2 2.27M Avg daily vol (3M) 2.59M

TPST metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.81
Market cap
$12.28M

Price action

20 metrics
Price change (1W)
-2.1%
Price change (30D)
-22.7%
Price change (3M)
-25.6%
Price change (6M)
-49.0%
Price change (YTD)
-71.7%
Price change (1Y)
-92.5%
Trailing year
Price change (5Y)
—
52-week high
$11.83
52-week low
$0.76
Change from 52-week high
-93.1%
Change from 52-week low
+7.4%
Annualized volatility
126.8%
Annualized volatility (3M)
169.9%
Beta
0.8
RSI (14D)
44.7
Price vs SMA 50
-15.7%
Price vs SMA 200
-53.2%
Avg volume (3M)
2.59M
Relative volume
0.9
Average dollar volume
$2.80M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
14.81M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
41.6×
reciprocal yield 2.4%
P / book
—
FCF yield
-168.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-329.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-45.1%
Operating margin
-28,585.1%
Trailing 12 months
Net margin
-28,670.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$40.64M
Net income (TTM)
−$40.47M
Trailing 12 months
Diluted EPS (TTM)
$-3.97
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.07

Growth

11 metrics
Revenue growth YoY
-1.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$295,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+300.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-420.1%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$58.66M
Free cash flow (TTM)
−$20.73M
Quick ratio
0.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$779,000
Total assets
$9.63M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$20.73M
Capital expenditures (TTM)
$0
R&D (TTM)
$3.04M
SG&A (TTM)
$15.85M
Stock compensation (TTM)
$1.77M
R&D / revenue
—
Stock compensation / revenue
601.7%

Ownership (13F)

3 metrics
13F filers
21
13F filer change QoQ
-1
Institutional ownership
8.7%

Short interest

3 metrics
Short interest
2.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
35 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1544227 CUSIP 87978U207 Visit website Investor relations